Eicosapentaenoic Acid (epa) Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Eicosapentaenoic Acid (epa) interacts with medications. The heart of this page is the interaction list — every drug Eicosapentaenoic Acid (epa) is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Eicosapentaenoic Acid (epa) is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Eicosapentaenoic Acid (epa) against your medication
Add one medicationEicosapentaenoic Acid (epa) Drug Interactions: The Bottom Line
From the HelloPharmacist Editorial Team · Updated July 2026Based on the available evidence, Eicosapentaenoic Acid (epa) drug interactions carry a moderate but manageable level of risk for most people, centered on blood pressure medicines and blood thinners. None of the listed interactions are rated major, and every one falls into just two moderate categories rather than many separate concerns.
The best-documented concern is with antihypertensive drugs, since fish oils containing EPA can lower blood pressure on their own and may add to the effect of these medicines, so blood pressure could drop more than expected. There is also a theoretical bleeding concern with anticoagulant and antiplatelet drugs, because human research shows EPA can make platelets less sticky. Anyone on a blood thinner or closely managed blood pressure treatment should watch for signs like unusual bruising or lightheadedness.
Although hundreds of medications appear on the interaction list, they all trace back to these two shared effects, not to hundreds of separate problems. Much of the bleeding concern remains theoretical and has not been shown to cause meaningful harm in most people, while the blood pressure effect is simply additive rather than dangerous on its own.
Based on HelloPharmacist’s Eicosapentaenoic Acid (epa) interaction data and reviewed under our editorial standards.
Drugs that interact with Eicosapentaenoic Acid (epa)
289 medications have a known interaction with Eicosapentaenoic Acid (epa), graded by severity. Select any drug for the full evidence-based detail.
Don’t want to scroll the list? Just ask.
Tell us the medications you take and we’ll check each one against Eicosapentaenoic Acid (epa) using our pharmacist-reviewed interaction data.
AI summaries are generated from our Eicosapentaenoic Acid (epa) interaction data for education only — always confirm with your pharmacist. How we use AI
No drugs match “”.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Eicosapentaenoic Acid (epa) combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
The kinds of drugs Eicosapentaenoic Acid (epa) affects
Every type of medication (drug category) Eicosapentaenoic Acid (epa) is known to interact with. Open any category for the detail — or search your exact drug in the checker above.
Anticoagulant/Antiplatelet Drugs
Theoretically, EPA may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
In human research, taking EPA has been shown to inhibit platelet aggregation.
Antihypertensive Drugs
Theoretically, taking EPA with antihypertensive drugs might increase the risk of hypotension.
Fish oils containing EPA can lower blood pressure and might have additive effects in patients treated with antihypertensives; use with caution.
Eicosapentaenoic Acid (epa): Uses, Safety & Side Effects
EPA is an omega-3 fatty acid found mostly in fatty fish and fish oil, and it is best known for lowering high triglycerides. It may also help with inflammation and mood in some people, but evidence varies by condition. Talk with your pharmacist or doctor before starting, especially if you take blood thinners or have a fish allergy.
- Part used
- Omega-3 fatty acid derived mainly from fatty fish and fish oil; also from algae
- Common forms
- Softgel capsules, liquid fish oil, prescription-strength capsules, algae-based supplements
- Heart and triglyceride health
- Inflammation
- Mood and depression support
- Joint comfort
- General omega-3 supplementation
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
EPA is generally well tolerated for most adults at typical supplement doses.
Insufficient reliable information available; avoid using.
Read the full pregnancy detailInsufficient reliable information available; avoid using.
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
Eicosapentaenoic acid (EPA) is a type of omega-3 fatty acid. The body cannot make enough of it on its own, so we get it mainly from foods like salmon, sardines, mackerel, and anchovies. It is also made by certain types of marine algae, which is the original source that fish get it from.
EPA is one of the two main long-chain omega-3 fats in fish oil. The other is DHA (docosahexaenoic acid). Many supplements contain both EPA and DHA, but some products are made to contain mostly EPA.
People take EPA supplements for heart health, high triglycerides, inflammation, and mood. It comes in fish oil capsules, liquid oils, prescription products, and algae-based options for people who prefer to avoid fish.
How it works
EPA is a building block your body uses to make signaling molecules that help control inflammation. Unlike some other fats that can promote inflammation, EPA helps make compounds that tend to calm it down.
EPA can also lower the amount of triglycerides your liver makes and releases into the blood. It may have mild effects on blood clotting and blood vessel function as well.
Many of these effects come from laboratory and clinical research, but scientists are still learning exactly how EPA produces its benefits in different conditions.
Does Eicosapentaenoic Acid (epa) work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
Effective Hypertriglyceridemia
Oral prescription ethyl-EPA 4 grams daily reduces triglyceride levels in patients with hypertriglyceridemia, especially in severe cases. It is unclear if oral EPA supplements are beneficial in hypertriglyceridemia.
Possibly Effective Depression
Oral EPA seems to reduce symptoms of depression, especially in patients already being treated with conventional antidepressants.
Possibly Effective Migraine headache
Oral EPA may reduce the number of days with a migraine each month in some adults with chronic or episodic migraine.
Possibly Effective Myocardial infarction (MI)
Oral prescription ethyl-EPA reduces the risk of MI when used as an adjunct to statin therapy in patients with cardiovascular disease (CVD) risk. Oral EPA supplements also seem to be beneficial for this purpose.
Also studied for 42 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Age-related macular degeneration (AMD)
It is unclear if oral EPA is beneficial for AMD prevention.
Insufficient Reliable Evidence To Rate Allergic rhinitis (hay fever)
Although there has been interest in using oral EPA for allergic rhinitis, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Alzheimer disease
It is unclear if oral EPA is beneficial for Alzheimer disease prevention.
Insufficient Reliable Evidence To Rate Asthma
Although there has been interest in using oral EPA for asthma, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Atopic dermatitis (eczema)
Although there has been interest in using oral EPA for atopic dermatitis, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Attention deficit-hyperactivity disorder (ADHD)
Oral EPA has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Behcet disease
Although there has been interest in using oral EPA for Behcet disease, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Bipolar disorder
Oral fish oil in doses providing 1-2 grams EPA may be beneficial for symptoms of depression in patients with bipolar disorder. It is unclear if EPA alone is beneficial.
Insufficient Reliable Evidence To Rate Borderline personality disorder
It is unclear if oral EPA is beneficial for improving symptoms of borderline personality disorder.
Insufficient Reliable Evidence To Rate Cachexia
It is unclear if oral EPA is beneficial for maintaining lean body mass in patients undergoing chemotherapy.
Insufficient Reliable Evidence To Rate Chemotherapy-induced diarrhea
It is unclear if oral EPA is beneficial for preventing diarrhea during treatment with chemotherapy.
Insufficient Reliable Evidence To Rate Chemotherapy-induced nausea and vomiting (CINV)
It is unclear if oral EPA is beneficial for preventing nausea and vomiting during treatment with chemotherapy.
Insufficient Reliable Evidence To Rate Chemotherapy-induced peripheral neuropathy
It is unclear if oral EPA is beneficial for preventing peripheral neuropathy during treatment with chemotherapy.
Insufficient Reliable Evidence To Rate Chemotherapy-related fatigue
It is unclear if oral EPA is beneficial for preventing fatigue during treatment with chemotherapy.
Insufficient Reliable Evidence To Rate Cognitive function
It is unclear if oral EPA alone is beneficial for improving cognitive function.
Insufficient Reliable Evidence To Rate Colorectal adenoma
Taking oral EPA with aspirin might reduce the development of new colorectal adenomas. However, it is unclear if oral EPA alone is beneficial.
Insufficient Reliable Evidence To Rate Coronary heart disease (CHD)
It is unclear if oral EPA alone is beneficial for CHD.
Insufficient Reliable Evidence To Rate Cystic fibrosis
Although there has been interest in using oral EPA for cystic fibrosis, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Diabetes
It is unclear if oral EPA is beneficial for glycemic control.
Insufficient Reliable Evidence To Rate Dysmenorrhea
Although there has been interest in using oral EPA for dysmenorrhea, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Exercise-induced muscle damage
It is unclear if oral EPA alone is beneficial for preventing exercise-induced muscle damage.
Insufficient Reliable Evidence To Rate Fractures
Oral EPA has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Huntington disease
It is unclear if oral EPA is beneficial for this condition.
Insufficient Reliable Evidence To Rate Hypercholesterolemia
It is unclear if oral EPA is beneficial for improving lipid levels.
Insufficient Reliable Evidence To Rate IgA nephropathy
Although there has been interest in using oral EPA for IgA nephropathy, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Intrauterine growth restriction (IUGR)
It is unclear if oral EPA during pregnancy reduces the risk of IUGR.
Insufficient Reliable Evidence To Rate Lung cancer
It is unclear if oral EPA is beneficial for lung cancer treatment.
Insufficient Reliable Evidence To Rate Menopausal symptoms
It is unclear if oral EPA reduces hot flashes after menopause.
Insufficient Reliable Evidence To Rate Metabolic syndrome
Although there has been interest in using oral EPA for metabolic syndrome, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Muscle strength
It is unclear if oral EPA is beneficial for increasing muscle strength.
Insufficient Reliable Evidence To Rate Physical performance
Taking EPA does not seem to improve physical performance in patients requiring mechanical ventilation. It is unclear if oral EPA is beneficial for increasing physical performance in older adults.
Insufficient Reliable Evidence To Rate Postoperative infection
Oral EPA has only been evaluated in combination with other ingredients; its effect when used alone is unclear.
Insufficient Reliable Evidence To Rate Postoperative recovery
It is unclear if oral EPA helps to maintain postoperative lean body mass.
Insufficient Reliable Evidence To Rate Pregnancy-induced hypertension
It is unclear if oral EPA during pregnancy reduces the risk of hypertension.
Insufficient Reliable Evidence To Rate Prostate cancer
It is unclear if oral EPA is beneficial for prostate cancer treatment or prevention.
Insufficient Reliable Evidence To Rate Psoriasis
It is unclear if oral EPA is beneficial in psoriasis.
Insufficient Reliable Evidence To Rate Quality of life
It is unclear if oral EPA is beneficial for improving quality of life in patients with cancer.
Insufficient Reliable Evidence To Rate Schizophrenia
Evidence for the use of oral EPA in schizophrenia is conflicting.
Insufficient Reliable Evidence To Rate Systemic lupus erythematosus (SLE)
Although there has been interest in using oral EPA for SLE, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Systemic lupus erythematosus (SLE) nephritis
Although there has been interest in using oral EPA for SLE nephritis, there is insufficient reliable information about the clinical effects of EPA for this condition.
Insufficient Reliable Evidence To Rate Ulcerative colitis
It is unclear if oral EPA is beneficial for ulcerative colitis prevention and treatment.
Insufficient Reliable Evidence To Rate Wound healing
Although there has been interest in using oral EPA for wound healing, there is insufficient reliable information about the clinical effects of EPA for this condition.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
EPA is generally considered safe for most adults when taken at usual supplement doses. People who are allergic to fish or shellfish should be cautious and may prefer algae-based products.
If you take medicines that thin the blood or you have a bleeding disorder, talk with your doctor before using higher-dose omega-3 products, since they may slightly affect clotting. Let your surgical team know if you take EPA before any planned surgery.
For pregnancy and breastfeeding, omega-3s are commonly recommended from food and prenatal supplements, but you should confirm the right product and dose with your doctor. Choose purified products to limit exposure to mercury and other contaminants.
Side effects
The most common side effects are mild and involve the stomach. These include fishy burps or aftertaste, nausea, bloating, loose stools, or heartburn. Taking the supplement with food or using an enteric-coated product may help.
At higher doses, EPA may slightly increase the risk of bleeding or easy bruising. Some studies have noted a possible increase in an irregular heartbeat called atrial fibrillation with high-dose omega-3 use. If you notice unusual symptoms, stop and check with your doctor.
Eicosapentaenoic Acid (epa): Reported Adverse Effects
Documented safety reports on Eicosapentaenoic Acid (epa) from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
Orally, prescription EPA or EPA derived from fish oil is generally well tolerated in doses of up to 3 grams daily. Agal oil providing EPA seems to be well tolerated. Doses of EPA greater than 3 grams daily are possibly unsafe.
Intravenously, fish oil or omega-3 fatty acid lipid emulsions containing EPA seem to be well tolerated.
Most Common Adverse Effects:
Orally: Belching, diarrhea, epigastric discomfort, fishy aftertaste, and nausea.
Serious Adverse Effects (Rare):
Orally: Some case reports raise concerns about increased risk of bleeding with high doses.
Atrial fibrillation Cardiovascular
Orally, taking the prescription ethyl-EPA product (Vascepa, Amarin) 4 grams daily has been linked to a 1% greater risk of atrial fibrillation or atrial flutter that required hospitalization when compared with placebo.
- Prescribing information: Vascepa (icosapent ethyl). Amarin Pharma, Inc. Bridgewater, NJ, USA. Revised 12/2019. Available at: https://www.vascepa.com/assets/pdf/Vascepa_PI.pdf [Accessed 12/16/2019].
Bleeding Hematologic
Orally, reported side effects of EPA, as well as fish oils containing EPA and docosahexaenoic acid (DHA), have included nosebleed. There is some concern that taking high doses of oils providing EPA along with DHA might decrease blood coagulation and increase the risk of bleeding. To reduce this risk, the US Food and Drug Administration (FDA) recommends that consumers limit intake of EPA plus DHA to 3 grams daily, with no more than 2 grams daily from a dietary supplement. The prescription ethyl-EPA product (Vascepa, Amarin) 4 grams daily has been linked to bleeding in 12% of patients, compared with 10% in the placebo group. Serious bleeding occurred in 3% of the Vascepa group compared to 2% in the placebo group.
- Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
- FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-Rpt0272-38-Appendix-D-Reference
- FDA announces qualified health claims for omega-3 fatty acids. Available at: https://www.fda.gov/Food/LabelingNutrition/ucm072756.htm. Accessed April 15 2019.
- Prescribing information: Vascepa (icosapent ethyl). Amarin Pharma, Inc. Bridgewater, NJ, USA. Revised 12/2019. Available at: https://www.vascepa.com/assets/pdf/Vascepa_PI.pdf [Accessed 12/16/2019].
Diarrhea Gastrointestinal
Orally, reported side effects of EPA have included nausea, diarrhea, and epigastric discomfort. For fish oils containing EPA and docosahexaenoic acid, side effects can include fishy taste, belching, nausea, and loose stools.
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
- Rao A, Briskey D, Nalley JO, Ganuza E. Omega-3 eicosapentaenoic acid (EPA) rich extract from the microalga Nannochloropsis decreases cholesterol in healthy individuals: A double-blind, randomized, placebo-controlled, three-month supplementation study. Nut
- Mori T, Murasaki K, Yokoyama Y. Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study. J C
- Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomized double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46-50.
- Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
Irregular heartbeat Cardiovascular
Orally, taking the prescription ethyl-EPA product (Vascepa, Amarin) 4 grams daily has been linked to a 1% greater risk of atrial fibrillation or atrial flutter that required hospitalization when compared with placebo. New-onset atrial fibrillation was also more likely to occur in adults with stable cardiovascular disease who were taking 1800 mg daily of a highly purified ethyl-EPA product in another clinical trial. Prescription fish oil products in the U.S. must carry a warning regarding the risk for recurrent atrial fibrillation and flutter in adults taking 4-8 grams of fish oil daily. The European Medicines Agency (EMA) has also updated the product information for omega-3 acid ethyl esters to include an increased risk of atrial fibrillation when taken in doses of 4 grams daily. The EMA recommends cessation of use if atrial fibrillation develops.
- Prescribing information: Vascepa (icosapent ethyl). Amarin Pharma, Inc. Bridgewater, NJ, USA. Revised 12/2019. Available at: https://www.vascepa.com/assets/pdf/Vascepa_PI.pdf [Accessed 12/16/2019].
Pain Musculoskeletal
Orally, EPA may cause musculoskeletal pain in some patients, although results from clinical research are conflicting. In one clinical study, a higher percentage of patients treated with ethyl-EPA 2 or 4 grams daily experienced joint pain compared to placebo (3.4% and 1.7% vs 0.4%, respectively). However, in another study, slightly fewer patients taking ethyl-EPA 1.8 grams daily experienced joint, lumbar, or muscle pain compared to placebo (1.6% vs 2.0%, respectively).
- Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardi
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
Pruritus Dermatologic
Orally, reported side effects of EPA have included skin rash and itching.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no single standard dose of EPA for everyone, and the right amount depends on why you are taking it. Doses used for triglycerides are usually much higher than general wellness doses.
The best approach is to follow the product label and check with your pharmacist or doctor, especially if you are using a high-dose or prescription product. Look at the actual amount of EPA listed on the label, since total fish oil is not the same as EPA content.
Eicosapentaenoic Acid (epa) & Pregnancy
Eicosapentaenoic Acid (epa) & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 14 references that drive our Eicosapentaenoic Acid (epa) monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Prisco D, Paniccia R, Bandinelli B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998;1:105-12.
- Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 1995;123:911-8.
- Sacks FM, Hebert P, Appel LJ, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. J Hypertens 1994;12:209-13.
- Vandongen R, Mori TA, Burke V, et al. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension 1993;22:371-9. PubMed
- FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-Rpt0272-38-Appendix-D-Reference
- Terano T, Hirai A, Hamazaki T, et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983;46:321-31.. PubMed
- Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. PubMed
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8. PubMed
- Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardi PubMed
- FDA announces qualified health claims for omega-3 fatty acids. Available at: https://www.fda.gov/Food/LabelingNutrition/ucm072756.htm. Accessed April 15 2019.
- Prescribing information: Vascepa (icosapent ethyl). Amarin Pharma, Inc. Bridgewater, NJ, USA. Revised 12/2019. Available at: https://www.vascepa.com/assets/pdf/Vascepa_PI.pdf [Accessed 12/16/2019].
- Rao A, Briskey D, Nalley JO, Ganuza E. Omega-3 eicosapentaenoic acid (EPA) rich extract from the microalga Nannochloropsis decreases cholesterol in healthy individuals: A double-blind, randomized, placebo-controlled, three-month supplementation study. Nut PubMed
- Mori T, Murasaki K, Yokoyama Y. Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study. J C PubMed
- Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomized double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46-50.
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Eicosapentaenoic Acid (epa): Common Questions
What is Eicosapentaenoic Acid (epa) used for, and does it work?
Does Eicosapentaenoic Acid (epa) interact with prescription medications?
How are Eicosapentaenoic Acid (epa) interactions rated?
Is it safe to take Eicosapentaenoic Acid (epa) with my medications?
Where does this Eicosapentaenoic Acid (epa) interaction information come from?
What is EPA used for?
What is the difference between EPA and DHA?
Can I get EPA without eating fish?
Is it safe to take EPA every day?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Have a question about Eicosapentaenoic Acid (epa)?
Our pharmacists answer your medication & supplement questions — free.